Latest News

Diabetes drug shows promise in reducing Alzheimer's disease in an experimental model

The diabetic drug, pramlintide, reduces amyloid-beta peptides, a major component of Alzheimer's disease in the brain and improves learning and memory in two experimental Alzheimer's disease models, researchers have discovered. These results also found Alzheimer's disease patients have a lower level of amylin in blood compared to those without this disease, and may provide a new avenue for both treatment and diagnosis of Alzheimer's disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Motivation explains disconnect between testing, real-life functioning for seniors

  • Novel technologies advance brain surgery to benefit patients

  • Mutated gene linked to both autism, intellectual disability

  • New concerns over top-selling blood thinning drug after investigation

  • Immune response may cause harm in brain injuries, disorders

  • New mechanism for neurodegeneration found

  • New tools help neuroscientists analyze 'big data'

  • Six new genetic risk factors for Parkinson's found

  • CEOs who motivate with 'fightin' words' shoot themselves in the foot

  • Knowledgeable consumers more likely to buy when given fewer options

  •